IFNA1 and prostate carcinoma: Docetaxel with bicalutamide treatment significantly upregulated IFN-stimulated genes in xenografted tumors (Figure 5G), again consistent with results in prostate cancer cell lines (Figure 4D and Figure S5D-E).